Radiopharmaceutical developer Navidea Biopharmaceuticals has received a patent extension for its Lymphoseek radiopharmaceutical.
The company reported that the U.S. Patent and Trademark Office has extended the duration of U.S. patent No. 6,409,990 for another five years, until May 2025. The patent covers the technology behind Lymphoseek, a technetium-based radiopharmaceutical that has been licensed to Cardinal Health.
